181 related articles for article (PubMed ID: 36138073)
1. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.
Davidson C; Taggart D; Sims AH; Lonergan DW; Canel M; Serrels A
Br J Cancer; 2022 Nov; 127(10):1893-1905. PubMed ID: 36138073
[TBL] [Abstract][Full Text] [Related]
2. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
[TBL] [Abstract][Full Text] [Related]
3. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Jiang H; Liu X; Knolhoff BL; Hegde S; Lee KB; Jiang H; Fields RC; Pachter JA; Lim KH; DeNardo DG
Gut; 2020 Jan; 69(1):122-132. PubMed ID: 31076405
[TBL] [Abstract][Full Text] [Related]
4. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
5. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
6. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
[TBL] [Abstract][Full Text] [Related]
8. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
9. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.
Cao XY; Zhang XX; Yang MW; Hu LP; Jiang SH; Tian GA; Zhu LL; Li Q; Sun YW; Zhang ZG
Biochem Biophys Res Commun; 2018 May; 499(3):584-593. PubMed ID: 29621546
[TBL] [Abstract][Full Text] [Related]
10. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
11. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
[TBL] [Abstract][Full Text] [Related]
12. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
13. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract][Full Text] [Related]
15. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
[TBL] [Abstract][Full Text] [Related]
16. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy.
Murphy KJ; Zhu J; Trpceski M; Pereira BA; Timpson P; Herrmann D
Biochem Soc Trans; 2022 Aug; 50(4):1129-1141. PubMed ID: 35929603
[TBL] [Abstract][Full Text] [Related]
18. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
19. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
20. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
